STOCK TITAN

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Orchestra BioMed Holdings (Nasdaq: OBIO) has announced its participation in the upcoming Jefferies London Healthcare Conference, scheduled for November 19-21, 2024, in London, UK. The company will engage in a fireside chat presentation on Tuesday, November 19, 2024, at 1:00 PM GMT.

The presentation will be accessible via webcast, and a replay will remain available on the Orchestra BioMed website's Events section for 90 days afterward. Company management will also be available for one-on-one meetings during the conference.

Orchestra BioMed Holdings (Nasdaq: OBIO) ha annunciato la sua partecipazione alla prossima Jefferies London Healthcare Conference, in programma dal 19 al 21 novembre 2024, a Londra, Regno Unito. L'azienda parteciperà a una presentazione in stile fireside chat martedì 19 novembre 2024, alle 13:00 GMT.

La presentazione sarà disponibile tramite webcast, e una registrazione rimarrà accessibile nella sezione Eventi del sito web di Orchestra BioMed per 90 giorni successivi. La gestione dell'azienda sarà anche disponibile per incontri individuali durante la conferenza.

Orchestra BioMed Holdings (Nasdaq: OBIO) ha anunciado su participación en la próxima Jefferies London Healthcare Conference, programada del 19 al 21 de noviembre de 2024, en Londres, Reino Unido. La compañía realizará una presentación en formato fireside chat el martes 19 de noviembre de 2024, a la 1:00 PM GMT.

La presentación estará disponible a través de un webcast, y una repetición estará disponible en la sección de Eventos del sitio web de Orchestra BioMed durante 90 días después de eso. La dirección de la empresa también estará disponible para reuniones uno a uno durante la conferencia.

Orchestra BioMed Holdings (Nasdaq: OBIO)는 2024년 11월 19일부터 21일까지 영국 런던에서 열리는 제프리즈 런던 헬스케어 컨퍼런스에 참가할 것이라고 발표했습니다. 회사는 2024년 11월 19일 화요일 오후 1시 GMT에 화 fireside chat 프레젠테이션에 참여할 예정입니다.

이 프레젠테이션은 웹캐스트를 통해 접근 가능하며, 이후 90일 동안 Orchestra BioMed 웹사이트의 이벤트 섹션에서 재생할 수 있습니다. 회사의 경영진은 또한 컨퍼런스 동안 일대일 미팅에 참석할 예정입니다.

Orchestra BioMed Holdings (Nasdaq: OBIO) a annoncé sa participation à la prochaine Jefferies London Healthcare Conference, prévue du 19 au 21 novembre 2024 à Londres, Royaume-Uni. L'entreprise participera à une présentation sous forme de fireside chat le mardi 19 novembre 2024 à 13h00 GMT.

La présentation sera accessible par webcast, et un enregistrement restera disponible dans la section Événements du site web d'Orchestra BioMed pendant 90 jours après. La direction de l'entreprise sera également disponible pour des réunions individuelles lors de la conférence.

Orchestra BioMed Holdings (Nasdaq: OBIO) hat seine Teilnahme an der bevorstehenden Jefferies London Healthcare Conference angekündigt, die vom 19. bis 21. November 2024 in London, UK, stattfindet. Das Unternehmen wird am Dienstag, den 19. November 2024, um 13:00 Uhr GMT eine Präsentation im Fireside-Chat-Format halten.

Die Präsentation wird über einen Webcast zugänglich sein, und eine Aufzeichnung wird für 90 Tage im Veranstaltungsbereich der Website von Orchestra BioMed verfügbar sein. Das Management des Unternehmens wird während der Konferenz auch für Einzelgespräche zur Verfügung stehen.

Positive
  • None.
Negative
  • None.

NEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies London Healthcare Conference being held in London, UK from November 19-21, 2024.

Details of the presentation are shown below.

Format: Fireside Chat
Date: Tuesday, November 19, 2024
Time: 1:00 PM GMT
Webcast: https://wsw.com/webcast/jeff315/obio/1840692

A replay of the webcast will be available on the Events section of the Orchestra BioMed website for 90 days following the presentation.

About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (also known as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the potential safety and efficacy of our product candidates, our collaboration with Medtronic and Terumo and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s quarterly report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 27, 2024, as updated by any risk factors disclosed under the heading “Item 1A. Risk Factors” in the Company’s subsequently filed quarterly reports on Form 10-Q.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:
Bob Yedid
LifeSci Advisors
516-428-8577
Bob@lifesciadvisors.com  

Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
484-682-4892
Kkirkellis@orchestrabiomed.com


FAQ

When is Orchestra BioMed (OBIO) presenting at the Jefferies London Healthcare Conference 2024?

Orchestra BioMed (OBIO) is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 1:00 PM GMT.

How long will the Orchestra BioMed (OBIO) Jefferies conference webcast be available for replay?

The webcast replay will be available on Orchestra BioMed's website Events section for 90 days following the November 19, 2024 presentation.

What type of presentation will Orchestra BioMed (OBIO) give at the Jefferies London Healthcare Conference?

Orchestra BioMed will participate in a fireside chat format presentation at the conference.

Where can I watch Orchestra BioMed's (OBIO) Jefferies conference presentation?

The presentation can be accessed via webcast at https://wsw.com/webcast/jeff315/obio/1840692

Orchestra BioMed Holdings, Inc. Ordinary Shares

NASDAQ:OBIO

OBIO Rankings

OBIO Latest News

OBIO Stock Data

205.39M
25.00M
22.14%
54.99%
2.06%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW HOPE